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of Ras Proteins
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The discovery of a new downstream target for the
Ras GTPases — a Nore1–Mst1 protein complex —
reveals a mechanism by which Ras can promote
apoptosis, and suggests that the influence of Ras on
cell survival or death depends upon the relative level
of activation of its various target proteins. 
It has been almost exactly 20 years since mutated Ras
genes, encoding forms of this GTPase locked in an
active conformation, were detected in human tumors.
Since that time, intensive effort has been invested in
understanding how excessive Ras activity in cells con-
tributes to human oncogenesis. As GTPases, Ras pro-
teins cycle between active GTP-bound and inactive
GDP-bound states. A wide variety of extracellular
signals promote the formation of the active GTP-
bound form of Ras proteins through a family of
guanine nucleotide exchange factors (GEFs). Once
active, Ras proteins can bind to a set of so-called
‘effector’ proteins, modulate their function, and
thereby influence multiple intracellular signal trans-
duction pathways. It has been assumed that constitu-
tively activated Ras increases the propensity of cells
to become tumorigenic because it deregulates these
intracellular signaling pathways. At first, attention
focused mainly on the role of Ras in promoting the
uncontrolled cell proliferation associated with cancer.
With the recent appreciation that cell death induced
by regulated apoptosis is a safeguard mechanism
used to prevent cells from reaching a fully neoplastic
state, the potential role of Ras in this process is now
attracting attention.
The first identified Ras targets, the Raf kinases, fit
the expectations of effectors of an oncogenic protein
since they potently stimulate the proliferation of many
cell types through the activation of the Raf/MEK/ERK
kinase cascade and oncogenically transform a number
of immortalized cell lines. Raf/ERK signaling has also
been shown to suppress apoptosis in many experi-
mental cell systems (for example see [1]) although in
some systems Raf/ERK activity can enhance apopto-
sis [2]. Another identified Ras target, phosphoinositide
3-kinase (PI 3-kinase), consistently prevents apopto-
sis in many cell systems. It does so by generating the
lipid second messengers phosphoinositide (3,4) P2
and phosphoinositide (3,4,5) P3 (PIP3). PIP3 promotes
the activation of a kinase cascade involving Akt,
whose substrates include proteins that modulate the
apoptotic signaling pathway (for a review, see [3]). 
PI 3-kinase can also suppress apoptosis through acti-
vation of the Rac GTPase, possibly through activation
of NF-κB [4]. Thus, the activation of PI 3-kinase asso-
ciated with excessive Ras activity may promote onco-
genesis by blunting the apoptosis-inducing stimuli
associated with oncogenic transformation.
A set of papers, the latest of which is by
Khokhlatchev et al. [5] in a recent issue of Current
Biology, has now provided strong support for the exis-
tence of yet another Ras effector pathway influencing
cell survival. This one has the opposite effect of PI
3-kinase in that it promotes apoptosis. As such, it may
suppress Ras-induced oncogenesis by preventing
transformed cells from surviving. This new signaling
pathway is mediated by Ras binding to a complex of
the Nore1 (novel Ras effector 1) and Mst1 (mammalian
Ste20-like kinase) proteins. Nore1 was first identified
as a protein with the ability to bind specifically to 
the active GTP-bound form of Ras [6]. However, Nore1
can also bind to the Ras-related Rap protein and 
most probably the Ras-related R-Ras protein. These
GTPases all have effector binding domains that are
extremely similar to that of Ras and bind to a similar
set of proteins in vitro. For reasons that are not under-
stood, however, these proteins have different biologi-
cal effects in cells.
That Nore1 is truly an effector of Ras is supported
by the finding that endogenous Nore1 forms a
complex with active endogenous Ras upon serum
stimulation of cells [6]. Comparable experiments for
Rap and R-Ras have not yet been performed, so their
role in Nore1–Mst1 function remains an open ques-
tion. Another criterion for a protein being considered
a Ras target is that its activity is affected by Ras
binding. This criterion has been difficult to evaluate 
for Nore1, however, because it has no detectable 
catalytic domain — its only recognizable protein motifs
are potential diacylglycerol- and SH3-domain-binding
sites near its amino terminus and a Ras-binding
domain at its carboxyl terminus.
Nevertheless, a clue to Nore1 function is provided
by the fact that it is most closely related to a family of
proteins encoded by the alternative splicing of the
putative tumor suppressor gene, RASSF1 (Ras asso-
ciation domain family). RNA transcripts of one of three
alternatively spliced versions of RASSF1, RASSF1A,
are missing in all small cell lung cancer cell lines
tested [7]. RASSF1A and RASSF1C mRNAs are also
missing in several other cancer cell lines [8]. Although
Nore1 itself has not yet been implicated as a tumor
suppressor gene product, it heterodimerizes with
RASSF1A in cells, and thus it may influence tumor
suppressor activity [9].
Given the exciting genetic evidence for RASSF1 in
human oncogenesis, understanding its biological
function is obviously of interest. One clue has come
from the observation that overexpression of RASSF1C
can promote apoptosis [10]. The new paper by
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Khokhlatchev et al. [5] now shows that Nore1 also
promotes apoptosis. In fact, these related proteins
may induce apoptosis by a similar mechanism, since
both RASSF1A and Nore1 bind to Mst1, a protein
kinase already implicated in the process of apoptosis.
Mst1 [11] is a Ste20-related member of the Group II
GC kinases that also promotes apoptosis upon over-
expression in cells [12,13]. Mst1 activates caspase 3,
which then stimulates the kinase activity of Mst1 by
cleaving off the inhibitory dimerization domain at the
carboxyl terminus of Mst1. Caspase-3-mediated cleav-
age and activation of Mst1 is also associated with
natural apoptotic stimuli, such as exposure of cells to
Fas ligand. However, relevant substrates of Mst1 have
not yet been found.
How does this function of Mst1 fit in with its newly
discovered role as a component of a Ras protein effec-
tor complex? Excessive Ras activity can produce apop-
tosis in both tissues [14] and immortalized cells [4]. In
the paper by Khokhlatchev et al. [5], multiple lines of evi-
dence support the involvement of a Ras–Nore–Mst1
complex in mediating Ras-induced apoptosis, at least in
NIH 3T3 and HEK293 cells exposed to tamoxifen. What
remains to be determined, however, is how Ras influ-
ences Mst1 function, since no change in kinase activity
was observed upon serum-induced binding to Ras. Full
activation of Mst1 requires phosphorylation [15], so
perhaps Ras-induced targeting of Mst1 to the plasma
membrane promotes this event.
Also, as Khokhlatchev et al. [5] suggest, future
experiments need to determine whether Ras binding
to Nore–Mst1 actually contributes to apoptosis regu-
lation during natural cell stimulation, since all studies
implicating this signaling pathway in apoptosis were
performed with overexpression of activated Ras. As
the authors note, it remains possible that this new Ras
effector pathway plays an as yet unknown biological
function. In fact, apoptosis induced by Fas ligand was
not inhibited in cells where Nore1 binding to Mst1 was
blocked.
If activation of Ras can promote both apoptosis via
Nore1 and cell survival via PI 3-kinase, how might a
cell make the life or death decision of which Ras
effector pathway to preferentially activate? Mecha-
nisms that promote preferential activation of specific
targets of Ras in response to extracellular signals are
beginning to be revealed (Figure 1). For example,
some evidence suggests that individual guanine
nucleotide exchange factors that activate GTPases
can promote the selection of particular GTPase effec-
tor pathways [16]. Moreover, the phosphorylation
state of effector proteins has been shown to differen-
tially affect their responsiveness to Ras [17]. Finally,
individual Ras family members appear to activate indi-
vidual effector pathways with different efficiencies.
For example, in COS7 cells H-Ras preferentially acti-
vates PI 3-kinase, while K-Ras preferentially activates
Raf kinase [18]. Interestingly, Khokhlatchev et al. [5]
find in their apoptosis system that K-Ras is more
effective than H-Ras at promoting apoptosis. The
authors speculate that the apoptosis-inducing effect
of the Nore1 pathway activated by K-Ras is not coun-
terbalanced by the survival-inducing effect of the 
PI 3-kinase pathway, as it is when signaling is medi-
ated by H-Ras. Together, these findings suggest that
different extracellular signals may promote survival or
apoptosis by modulating the specificity of Ras signal-
ing to its multiple effector proteins.
What about life and death decisions in oncogene-
sis? The tumor suppressor, RASSF1, may participate
in Ras-induced apoptosis either through heterodimer
formation with the Ras-binding Nore1 protein or
through its potential to bind directly to Ras [9]. If so,
the loss of RASSF1 expression may promote oncoge-
nesis by preventing Ras-induced apoptosis and thus
tip the balance of Ras signaling in favor of the sur-
vival-promoting effects of the Ras–PI 3-kinase signal-
ing cascade (Figure 2). Interestingly, K-Ras, not H-Ras,
is commonly activated by mutation in lung cancer [19]
where RASSF1 expression is frequently absent. Could
it be that loss of RASSF1 is particularly important in K-
Ras-induced oncogenesis to overcome the relative
inefficiency at which K-Ras activates the pro-survival
PI 3-kinase pathway compared with the pro-apoptotic
Nore1–Mst1 pathway? Perhaps RASSF1 expression
should be investigated in pancreatic cancer, where
K-Ras activation is also a common genetic event.
While these correlations are striking, contradictions
do exist in the literature. For example, in a different
study of Ras induction of apoptosis using rat embryo
fibroblasts, comparison of the effectiveness of K-Ras
and H-Ras in inducing apoptosis led to the opposite
conclusion. K-Ras was less effective than H-Ras in
Figure 1. Ras can both promote apoptosis through its associa-
tion with a Nore1–RASSF1–Mst1 complex and suppress apop-
tosis through its contribution to PI 3-kinase activation. Thus,
the influence of Ras on apoptosis may be determined by the
relative levels of activation of different effector pathways.
RASSF1 may also bind directly to active Ras. At least three
mechanisms for how selectivity is achieved in GTPase effector
activation have been proposed: 1) individual extracellular
signals may activate specific GEFs that participate in the the
selection of effectors for GTPases [16]; 2) post-translational
modification (e.g. phosphorylation) of a specific Ras effector,
such as a GEF for Ras-related Ral GTPases, may affect its
interaction with Ras [17]; 3) different Ras isoforms may activate
effectors with different efficiencies [18].
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inducing apoptosis, which correlated with more 
efficient activation of the Rac GTPase [20]. It is clear
that generalizations about the role of Ras in apoptosis
will be hard to come by since its effects are likely to
differ between cell types and the mechanisms of
apoptosis studied. Nevertheless, the discovery of the
Nore–RASSF1–Mst1 complex as a distinct Ras effec-
tor pathway for apoptosis will undoubtedly provoke
new studies that enhance our understanding of the
role of Ras in the life and death decisions of cells.
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Figure 2. The loss of the tumor suppressor RASSF1 may
suppress the ability of active GTP-bound Ras to promote
apoptosis through Nore1–Mst1, causing Ras to preferentially
activate the anti-apoptotic PI 3-kinase signaling cascade.
Together with the mitogenic stimulation induced by Raf and
Ral GEFs, this could predispose cells to oncogenic
transformation.
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